The Juvenile Rheumatoid Arthritis drugs in development market research report provides comprehensive information on the therapeutics under development for Juvenile Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Juvenile Rheumatoid Arthritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Juvenile Rheumatoid Arthritis and features dormant and discontinued products.
GlobalData tracks six drugs in development for Juvenile Rheumatoid Arthritis by six companies/universities/institutes. The top development phase for Juvenile Rheumatoid Arthritis is preclinical with four drugs in that stage. The Juvenile Rheumatoid Arthritis pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Juvenile Rheumatoid Arthritis pipeline products market are: Johnson & Johnson, LipUm and AstraZeneca.
The key targets in the Juvenile Rheumatoid Arthritis pipeline products market include T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80), Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1), and Interleukin 23 Subunit Alpha (Interleukin 23 Subunit p19 or IL23A).
The key mechanisms of action in the Juvenile Rheumatoid Arthritis pipeline product include Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) Inhibitor with one drug in Preclinical. The Juvenile Rheumatoid Arthritis pipeline products include three routes of administration with the top ROA being Subcutaneous and three key molecule types in the Juvenile Rheumatoid Arthritis pipeline products market including Monoclonal Antibody, and Fusion Protein.
Juvenile Rheumatoid Arthritis overview
Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in kids and teens. It typically causes joint pain and inflammation in the hands, knees, ankles, elbows and/or wrists. But, it may affect other body parts too . JIA used to be called juvenile rheumatoid arthritis (JRA), but the name changed because it is not a kid version of the adult disease. The term “juvenile arthritis” is used to describe all the joint conditions that affects kids and teens, including JIA
For a complete picture of Juvenile Rheumatoid Arthritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
